These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19755757)

  • 1. Managing depression and the appropriate use of SSRIs and SNRIs in primary care.
    Nakao M
    Intern Med; 2009; 48(18):1575-6. PubMed ID: 19755757
    [No Abstract]   [Full Text] [Related]  

  • 2. The ABCs of antidepressants. SSRIs, SNRIs, NDRIs: what's the difference?
    Health After 50 Sci Am Consum Health; 2016 Feb; 27(15):1-2. PubMed ID: 27062755
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants.
    Montgomery SA
    CNS Spectr; 2008 Jul; 13(7 Suppl 11):27-33. PubMed ID: 18622372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release.
    Peniston JH; Hu X; Potts SL; Wieman MS; Turk DC
    Postgrad Med; 2012 Mar; 124(2):114-22. PubMed ID: 22437221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) – New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability.
    Cosci F; Chouinard G; Chouinard VA; Fava GA
    Riv Psichiatr; 2018; 53(2):95-99. PubMed ID: 29674777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
    Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
    Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
    [No Abstract]   [Full Text] [Related]  

  • 7. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.
    Machado M; Iskedjian M; Ruiz I; Einarson TR
    Curr Med Res Opin; 2006 Sep; 22(9):1825-37. PubMed ID: 16968586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials.
    Machado M; Einarson TR
    J Clin Pharm Ther; 2010 Apr; 35(2):177-88. PubMed ID: 20456736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
    Hsiao MC; Liu CY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacological profile of SSRIs and SNRIs in the treatment of eating disorders.
    Capasso A; Petrella C; Milano W
    Curr Clin Pharmacol; 2009 Jan; 4(1):78-83. PubMed ID: 19149506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
    Lee SI; Keltner NL
    Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
    [No Abstract]   [Full Text] [Related]  

  • 12. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ Action mechanisms of modern antidepressives].
    Müller WE
    Pharm Unserer Zeit; 2004; 33(4):288-95. PubMed ID: 15287689
    [No Abstract]   [Full Text] [Related]  

  • 14. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
    Ishigooka J
    Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses.
    Machado M; Iskedjian M; Ruiz IA; Einarson TR
    Pharmacoeconomics; 2007; 25(11):979-90. PubMed ID: 17960955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of SSRIs and SNRIs in neuropathic pain.
    Lee YC; Chen PP
    Expert Opin Pharmacother; 2010 Dec; 11(17):2813-25. PubMed ID: 20642317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.
    Gougoulaki M; Lewis G; Nutt DJ; Peters TJ; Wiles NJ; Lewis G
    J Psychopharmacol; 2021 Aug; 35(8):919-927. PubMed ID: 33637001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
    Takahashi H; Kamata M; Yoshida K; Higuchi H; Shimizu T
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):351-3. PubMed ID: 15694247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteal phase and symptom-onset dosing of SSRIs/SNRIs in the treatment of premenstrual dysphoria: clinical evidence and rationale.
    Steiner M; Li T
    CNS Drugs; 2013 Aug; 27(8):583-9. PubMed ID: 23728922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
    Puech A; Montgomery SA; Prost JF; Solles A; Briley M
    Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.